TempraMed Announces Private Placement of up to C$2.5 Million

Executive Summary

• TempraMed Technologies Ltd. announced a non‑brokered private placement of up to 3,289,473 units at C$0.76 per unit, targeting gross proceeds of up to C$2.5 million.
• Each unit consists of one common share and one warrant allowing purchase of an additional share at C$1.00 for up to 18 months after closing.
• Proceeds will be used to fund new inventory, product development, global sales‑and‑marketing expansion, and general working capital.

Key Details

• Units Offered: Up to 3,289,473 units (each = 1 common share + 1 warrant).
• Price per Unit: C$0.76 → Maximum Gross Proceeds: C$2,500,000.
• Warrant Terms: Right to purchase one additional share at C$1.00, exercisable any time up to 18 months post‑closing.
• Closing Timeline: Anticipated on or before November 5, 2025 (subject to receipt of funds and regulatory compliance).
• Use of Proceeds:
• New inventory acquisition.
• Product development initiatives.
• Scaling of global sales and marketing operations.
• General working capital.
• Holding Period: Shares, warrants, and any shares issued upon warrant exercise subject to a four‑month + one‑day hold period in Canada from closing date.
• Insider Restrictions: Warrants issued to certain investors restricted from exercising if resulting ownership would exceed 9.99% of outstanding shares; no new insiders expected.
• Finder’s Compensation:
• Cash fee equal to 7% of gross proceeds.
• Finder’s Shares equal to 7% of the number of units placed by each finder.
• Contact Information:
• Ron Nagar – Chief Executive Officer ([email protected])
• Julia Becker – Vice President, Capital Markets (+1 604‑785‑0850, [email protected])

Notable Quotes

“We are pleased to secure this financing which will accelerate our product development and expand our global reach, reinforcing TempraMed’s leadership in temperature‑controlled medication solutions.” – Ron Nagar, CEO.